A single biosimilar claim saves our clients who use our Biosimilar Advantage Formulary^SM an average of $5,700. For some, that number jumps to $9,800 per claim. These aren’t future projections—this is happening right now and is just the beginning. 

The Biosimilar Revolution in Numbers 

The landscape has transformed dramatically since the Food and Drug Administration (FDA) approved Zarxio in 2015 as the first biosimilar to Neupogen. Today’s biosimilar market offers safe, effective alternatives to high-cost biologics that treat everything from cancer to autoimmune diseases—and the savings are substantial. 

Consider this: With Yusimry™ and Otulfi^® priced as much as 90% lower than their reference brands, Humira^® and Stelara^®, Mark Cuban Cost Plus Drug Company is challenging the high-cost status quo of biologic medications. When a single medication costs tens of thousands of dollars annually, these price reductions represent life-changing savings for patients and plan sponsors. 

What’s Happening Right Now 

The biosimilar pipeline continues to expand with new options: 

• Humira’s Competition Intensifies: Ten FDA-approved biosimilars now exist. While some indications are temporarily excluded due to exclusivity laws, these restricted uses account for less than 5% of all Humira prescriptions. Translation? Over 95% of members currently using Humira can switch to lower-cost biosimilar alternatives. 

New Biosimilar Options Across Key Therapy Areas: 

• Xolair (asthma/allergies): In March 2025, Celltrion’s Omlyclo became the first interchangeable biosimilar approved for all current Xolair indications. It is expected to launch in 2026 with two available strengths. 

• Prolia (osteoporosis): Jubbonti was approved as an interchangeable biosimilar in March 2024 and launched this month (June 2025). Additional Prolia biosimilars have been approved, with Stoboclo and Conexxence expected to be available this summer. 

• Actemra (rheumatoid arthritis): Avtozma by Celltrion was approved in January 2025, with the intravenous product expected to be released in August 2025. Fresenius’ Tyenne is currently available but not designated as interchangeable. 

Dozens of biosimilars are being developed for blockbuster drugs, including Stelara, Simponi, and Eylea. As these launch over the next few years, plan sponsors who establish biosimilar-friendly policies will be well-positioned to capture maximum savings. 

Overcoming the Adoption Challenge

Despite proven safety and efficacy, biosimilar adoption faces hurdles. Some biosimilars carry “skinny labels”—meaning they’re not approved for every indication the reference drug treats—due to patent issues (not safety concerns), and provider familiarity varies. However, interchangeability designation—allowing pharmacy-level substitution like generics—is accelerating uptake. 

Your Competitive Advantage

Our Biosimilar Advantage Formulary doesn’t just follow market trends—it anticipates them. By positioning proven biosimilars as preferred options while excluding high-cost reference brands in key categories, we’re helping clients capture savings today while building the foundation for tomorrow’s cost management. 

The formulary design carefully analyzes FDA-approved indications, real-world pricing, and rebate structures to maximize savings and clinical outcomes. 

The bottom line: Biosimilars aren’t just a cost-containment strategy—they’re becoming essential for sustainable healthcare benefits. With proven savings averaging $5,700 per claim and growing competition on the horizon, the question isn’t whether to embrace biosimilars but how quickly you can position your clients to benefit. 

Talk to us today about implementing our Biosimilar Advantage Formulary for your clients to get savings on their specialty drug spending.

About Serve You Rx®   
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what's best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for nearly 40 years, Serve You Rx can implement new groups in 30 days or less and say "yes" to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.